[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622773":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":51,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Peter MacCallum Cancer Centre, Australia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Photobiomodulation","EXPERIMENTAL","Participants will receive photobiomodulation therapy five times a week during the course of their radiation treatment. Upon completion of radiotherapy, if oral mucositis is still present, participants can choose to continue photobiomodulation treatment until oral mucositis has resolved. The frequency of photobiomodulation will be conducted at the discretion of the investigator.",[13],"Device: photobiomodulation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","photobiomodulation","photobiomodulation (low level laser therapy) application within and outside the oral cavity",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Sophie Beaumont, Bachelor of Dental surgery","CONTACT","03 85596443","sophie.beaumont@petermac.org",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Shae Beaton, Bachelor of oral health","shae.beaton@petermac.org",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Peter MacCallum Cancer Centre","RECRUITING","Melbourne","Victoria","3000","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],144.96332,-37.814,{"lat":43,"lon":42},[46,47,48],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},{"name":49,"role":50,"phone":20,"phoneExt":20,"email":20},"Sophie Beaumont, Bachelor of Dental Surgery","PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100622773","a-study-to-describe-the-effect-of-photobiomodulation-low-level-laser-therapy-in-reducing-the-severity-and-incidence-of-oral-mucositis-oral-ulceration-in-oral-cancer-patients-undergoing-radiation-treatment-100622773",false,"NCT07387978","A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment","A Pilot Study to Describe the Effect of Photobiomodulation in Reducing the Severity and Incidence of Oral Mucositis in Oral Cancer Patients Undergoing Radiation Treatment","PBM","Inclusion Criteria:\n\n* Patient has provided written informed consent using the PBM PICF\n* Age ≥ 18 years of age at Screening\n* Histological diagnosis of HNC of the oral cavity with no evidence of macroscopic or microscopic residual disease post-surgery (R0 or R1 resection) with histopathological confirmation and no gross residual lymphadenopathy in the planned PBM treatment area\n* Planned treatment with RT or chemoradiotherapy to a dose of ≥ 50 Gy Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1)\n* Intact oral mucosa (no visible ulceration, dehiscence, or active infection)\n\nExclusion Criteria:\n\n* Gross macroscopic and\u002For microscopic residual disease post-surgery (R2 resection) or gross residual lymphadenopathy in the planned PBM treatment area\n* Prior RT to the head and neck including the oral or oropharyngeal mucosa\n* Prior cytotoxic chemotherapy in the last 3 months\n* Diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc)\n* Concurrent administration of cetuximab\n* Known to be pregnant or planning to become pregnant within the trial period\n* Diagnosis of epilepsy",true,"ALL","18 Years",{"count":65,"type":66},30,"ESTIMATED","INTERVENTIONAL",[69],"NA","The goal of this study is to describe the effect of photobiomodulation (PBM) on the incidence and severity of oral mucositis in post-operative oral cancer patients receiving radiotherapy +\u002F- chemotherapy.\n\nParticipants will receive PBM treatment five times a week throughout the course of their radiotherapy.\n\nThe main question it aims to answer is whether photobiomodulation reduces the incidence and severity of oral mucositis.",[72],"Oral Mucositis",[17,74,75,76,77,78],"low level laser therapy","head and neck cancer","oral cancer","radiotherapy","oral mucositis","2026-01-27",{"date":81,"type":82},"2026-02-04","ACTUAL",{"date":84,"type":82},"2025-11-26",{"date":86,"type":66},"2028-11",{"name":5,"class":6},1]